research 5α-Reductase inhibitors in androgenetic alopecia
Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
Search
for
Sort by
Research
600-630 / 1000+ results 
research Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
The review found that women using hair loss drugs like finasteride and dutasteride rarely reported sexual side effects.
research Frontal Fibrosing Alopecia: A Review
Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
research 5α‐Reductase inhibitors and prostatic disease
5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
research Therapeutic response of facial papules and inflammation in frontal fibrosing alopecia to low-dose oral isotretinoin
Low-dose oral isotretinoin improved hair loss and facial bumps in patients with a specific type of hair loss.
research Systematic review – alopecia areata and tofacitinib in paediatric patients
Tofacitinib may help treat hair loss in children with alopecia areata.
research Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia
5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.
research Rapid generation of homogenous tumor spheroid microtissues in a scaffold-free platform for high-throughput screening of a novel combination nanomedicine
A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.
research Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
research The Efficacy of Oral Finasteride and Dutasteride in the Treatment of Female Pattern Hair Loss and Frontal Fibrosing Alopecia in Women: A Scoping Review
Finasteride and dutasteride can improve hair loss in women, but more research is needed.
research Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
research Significance of RU58841 as a therapeutic agent effecting androgen receptor molecular interactions in human hair follicles.
RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
research Synthesis of mimics of steroid A ring as potential enzyme inhibitors
Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research The antiandrogenic effect of finasteride against a mutant androgen receptor
Finasteride may improve prostate cancer treatment outcomes.
research What do we know about 5-alpha reductase inhibitors?
5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Frontal fibrosing alopecia: a review of eleven patients
Most treatments for Frontal Fibrosing Alopecia are ineffective, but early anti-inflammatory therapy may help and the condition may stabilize over time.
research Comparison of Efficacy and Specificity in Cancer‐Targeting Prodrug Conjugates
The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
research Two Birds that Exclude Each Other: The Renbök Phenomenon
Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
research ダブルストロボレンジファインダの開発(特別講演)(画像センシングおよび一般)
Some prostate cancers have gene changes that may affect treatment with certain drugs.
research 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.